These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7989288)

  • 1. Valproate pretreatment for the difficult-to-treat patient with OCD.
    Deltito JA
    J Clin Psychiatry; 1994 Nov; 55(11):500. PubMed ID: 7989288
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacotherapy of obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Price LH
    J Clin Psychiatry; 1992 Apr; 53 Suppl():29-37. PubMed ID: 1532962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressants in the treatment of premature ejaculation.
    Balon R
    J Sex Marital Ther; 1996; 22(2):85-96. PubMed ID: 8743620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder?
    Koran LM; Mueller K; Maloney A
    J Clin Psychopharmacol; 1996 Jun; 16(3):253-4. PubMed ID: 8784659
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
    Flament MF; Bisserbe JC
    J Clin Psychiatry; 1997; 58 Suppl 12():18-22. PubMed ID: 9393392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
    Carpenter LL; McDougle CJ; Epperson CN; Price LH
    Drug Saf; 1996 Aug; 15(2):116-34. PubMed ID: 8884163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pica and the obsessive-compulsive spectrum disorders.
    Stein DJ; Bouwer C; van Heerden B
    S Afr Med J; 1996 Dec; 86(12 Suppl):1586-8, 1591-2. PubMed ID: 9180801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
    Hantouche EG; Bouhassira M; Lancrenon S
    Encephale; 2000; 26(6):73-83. PubMed ID: 11217541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential response of psychotic and obsessive symptoms to risperidone in an adolescent.
    Dryden-Edwards RC; Reiss AL
    J Child Adolesc Psychopharmacol; 1996; 6(2):139-45. PubMed ID: 9231306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective serotonin reuptake inhibitors in OCD.
    Montgomery SA; Bullock T; Fineberg N; Montgomery D
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():255A-256A. PubMed ID: 1498831
    [No Abstract]   [Full Text] [Related]  

  • 13. Medication optimization during clozapine treatment.
    Suppes T; Rush AJ
    J Clin Psychiatry; 1996 Jul; 57(7):307-8. PubMed ID: 8666574
    [No Abstract]   [Full Text] [Related]  

  • 14. Sertraline (Lustral) and paroxetine (Seroxat)--new drugs for the treatment of depression.
    Drug Ther Bull; 1991 Jun; 29(12):46-7. PubMed ID: 1834449
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug treatment of obsessive-compulsive disorders--a comparative study of the effectiveness of clomipramine and fluoxetine].
    Volk S
    Fortschr Neurol Psychiatr; 1995 Jun; 63 Suppl 1():28-32. PubMed ID: 7635392
    [No Abstract]   [Full Text] [Related]  

  • 16. Nicotine augmentation for refractory obsessive-compulsive disorder. A case report.
    Pasquini M; Garavini A; Biondi M
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):157-9. PubMed ID: 15610960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacotherapy of obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Price LH
    Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
    Etain B; Bonnet-Perrin E
    Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy assessment of fluoxetine treatment of outpatients with obsessive-compulsive disorder: a preliminary report].
    Wandzel L
    Psychiatr Pol; 1997; 31(4):429-35. PubMed ID: 9527686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.